In addition, PSMB3 exon 4 skipping was also not observed when treating either A549 NSCLC cells or IMR-90 non-malignant lung cells with the SF3B1 inhibitor pladienolide B (Figure S4A). Here, PSMB3 is linked to non-small cell lung carcinoma.